Trial Profile
A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 03 May 2016 Status changed from recruiting to discontinued.
- 22 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Jun 2015 New trial record